4.7 Article

Detection of Clinically Relevant Genetic Variants in Autism Spectrum Disorder by Whole-Genome Sequencing

Journal

AMERICAN JOURNAL OF HUMAN GENETICS
Volume 93, Issue 2, Pages 249-263

Publisher

CELL PRESS
DOI: 10.1016/j.ajhg.2013.06.012

Keywords

-

Funding

  1. Autism Speaks
  2. Autism Speaks Canada
  3. National Institutes of Health [NIMH R01MH098114-01]
  4. National Science and Technology Ministry Project 973 program [2011CB809200]
  5. National Science and Technology Ministry Project 863 program [2012AA02A201]
  6. National Natural Science Foundation of China Major Program [30890032]
  7. Shenzhen Municipal Government of China [CXB201108250094A, CXB201108250096A, ZYC200903240080A, ZYC201105170397A, ZYC201105170394A]
  8. Enterprise Key Laboratory
  9. Guangdong Province (the Guangdong Enterprise Key Laboratory of Human Disease Genomics)
  10. Shenzhen Key Laboratory of Gene Bank for National Life Science (National Gene Bank Project of China)
  11. NeuroDevNet
  12. Canadian Institutes for Advanced Research
  13. University of Toronto McLaughlin Centre
  14. Genome Canada/Ontario Genomics Institute
  15. government of Ontario
  16. Canadian Institutes of Health Research
  17. Hospital for Sick Children Foundation
  18. Autism Speaks Postdoctoral Fellowship in Translational Research
  19. Novartis
  20. Seaside Therapeutics
  21. Sanofi Canada
  22. SynaptDx

Ask authors/readers for more resources

Autism Spectrum Disorder (ASD) demonstrates high heritability and familial clustering, yet the genetic causes remain only partially understood as a result of extensive clinical and genomic heterogeneity. Whole-genome sequencing (WGS) shows promise as a tool for identifying ASD risk genes as well as unreported mutations in known loci, but an assessment of its full utility in an ASD group has not been performed. We used WGS to examine 32 families with ASD to detect de novo or rare inherited genetic variants predicted to be deleterious (loss-of-function and damaging missense mutations). Among ASD probands, we identified deleterious de novo mutations in six of 32 (19%) families and X-linked or autosomal inherited alterations in ten of 32 (31%) families (some had combinations of mutations). The proportion of families identified with such putative mutations was larger than has been previously reported; this yield was in part due to the comprehensive and uniform coverage afforded by WGS. Deleterious variants were found in four unrecognized, nine known, and eight candidate ASD risk genes. Examples include CAPRIN1 and AFF2 (both linked to FMR1, which is involved in fragile X syndrome), VIP (involved in social-cognitive deficits), and other genes such as SCN2A and KCNQ2 (linked to epilepsy), NRXN1, and CHD7, which causes ASD-associated CHARGE syndrome. Taken together, these results suggest that WGS and thorough bioinformatic analyses for de novo and rare inherited mutations will improve the detection of genetic variants likely to be associated with ASD or its accompanying clinical symptoms.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available